Grant ID DP220053
Awarded On August 17, 2022
Title Development of eRapa for the treatment of Familial Adenomatous Polyposis, a rare genetic disease associated with a high risk of colorectal cancer
Program Product Development Research
Award Mechanism Texas Company Product Development Awards
Institution/Organization Rapamycin Holdings Inc.
Principal Investigator/Program Director Shannon Kingman
Cancer Sites Colorectal, Prostate
Contracted Amount $16,999,999*

*Pending contract negotiation

Lay Summary

Emtora Biosciences is a San Antonio, TX company that has developed eRapa, a novel form of the FDA-approved active ingredient rapamycin. Rapamycin has previously shown promise in treating gastrointestinal diseases and in cancer prevention, but is limited by toxicity. eRapa is targeted to the colon and is delivered at lower doses, resulting in lower toxicity. eRapa is being evaluated to prevent colorectal cancer in patients with Familial Adenomatous Polyposis (FAP). FAP is a rare genetic disease that results in 100's to 1000's of benign polyps forming in the colon as early as the teen years. It is an orphan indication. In mice, eRapa decreased the occurrence of polyps based on dosage levels, ...

Read More